{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:45:35Z","timestamp":1787024735248,"version":"build-2736575974"},"reference-count":234,"publisher":"Bentham Science Publishers Ltd.","issue":"33","funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["19-73-30012"],"award-info":[{"award-number":["19-73-30012"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>This review covers nanotherapeutic strategies for solving the global problems associated with Alzheimer's disease (AD). The most dramatic factor contributing humanistic, social and economic urgency of the situation is the incurability of the disease, with the drug intervention addressing only AD symptoms and retarding their progress. Key sources behind these challenges are the inability of the early diagnosis of AD, the lack of comprehensive information on the molecular mechanism of the pathogenesis, the bloodbrain barrier obstacles, and the insufficient effectiveness of currently available drugs and therapeutic strategies. The application of nanocarriers allows part of these problems to be solved, together with the improvement of drug bioavailability, prolonged circulation, and overcoming\/bypassing the biological barriers. To this date, numerous types and subtypes of nanocarriers are developed and reviewed, the majority of which can be adapted for the treatment of various diseases. Therefore, herein, nanotherapy strategies are specifically categorized in term of the administration routes of AD medicines, with the noninvasive, i.e., transdermal, oral, and intranasal routes emphasized. Further, benefits\/ limitations of various nanocarriers are discussed, and perspectives of their application are highlighted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0929867330666221115103513","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T23:48:45Z","timestamp":1668556125000},"page":"3743-3774","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Recent Nanoscale Carriers for Therapy of Alzheimer's Disease: Current Strategies and Perspectives"],"prefix":"10.2174","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2981-445X","authenticated-orcid":true,"given":"Lucia","family":"Zakharova","sequence":"first","affiliation":[{"name":"Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Kazan, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0406-4066","authenticated-orcid":true,"given":"Gulnara","family":"Gaynanova","sequence":"additional","affiliation":[{"name":"Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Kazan, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1825-7803","authenticated-orcid":true,"given":"Elmira","family":"Vasilieva","sequence":"additional","affiliation":[{"name":"Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Kazan, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2785-5992","authenticated-orcid":true,"given":"Leysan","family":"Vasileva","sequence":"additional","affiliation":[{"name":"Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Kazan, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0559-1095","authenticated-orcid":true,"given":"Rais","family":"Pavlov","sequence":"additional","affiliation":[{"name":"Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Kazan, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8019-353X","authenticated-orcid":true,"given":"Ruslan","family":"Kashapov","sequence":"additional","affiliation":[{"name":"Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Kazan, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Petrov","sequence":"additional","affiliation":[{"name":"Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Kazan, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2241-9764","authenticated-orcid":true,"given":"Oleg","family":"Sinyashin","sequence":"additional","affiliation":[{"name":"Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Kazan, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"119129","DOI":"10.1016\/j.lfs.2021.119129","volume":"276","author":"Se Thoe E.","year":"2021","unstructured":"Se Thoe E.; Fauzi A.; Tang Y.Q.; Chamyuang S.; Chia A.Y.Y.; A review on advances of treatment modalities for Alzheimer\u2019s disease. Life Sci 2021,276,119129-119151","journal-title":"Life Sci"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","volume":"308","author":"Davies P.","year":"1976","unstructured":"Davies P.; Maloney A.J.; Selective loss of central cholinergic neurons in Alzheimer\u2019s disease. Lancet 1976,308(8000),1403","journal-title":"Lancet"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/brain\/99.3.459","volume":"99","author":"Bowen D.M.","year":"1976","unstructured":"Bowen D.M.; Smith C.B.; White P.; Davison A.N.; Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976,99(3),459-496","journal-title":"Brain"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"111623","DOI":"10.1016\/j.biopha.2021.111623","volume":"139","author":"Nguyen T.T.","year":"2021","unstructured":"Nguyen T.T.; Nguyen T.T.D.; Nguyen T.K.O.; Vo T.K.; Vo V.G.; Advances in developing therapeutic strategies for Alzheimer\u2019s disease. Biomed Pharmacother 2021,139,111623-111632","journal-title":"Biomed Pharmacother"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14283\/jpad.2017.12","volume":"4","author":"Cummings J.","year":"2017","unstructured":"Cummings J.; Fox N.; Defining disease modifying therapy for Alzheimer\u2019s disease. J Prev Alzheimers Dis 2017,4(2),1-7","journal-title":"J Prev Alzheimers Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"111828","DOI":"10.1016\/j.exger.2022.111828","volume":"164","author":"Reiss A.B.","year":"2022","unstructured":"Reiss A.B.; Ahmed S.; Dayaramani C.; Glass A.D.; Gomolin I.H.; Pinkhasov A.; Stecker M.M.; Wisniewski T.; De Leon J.; The role of mitochondrial dysfunction in Alzheimer\u2019s disease: A potential pathway to treatment. Exp Gerontol 2022,164,111828-111836","journal-title":"Exp Gerontol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.17116\/jnevro20151156103-114","volume":"115","author":"Kukharsky M.S.","year":"2015","unstructured":"Kukharsky M.S.; Ovchinnikov R.K.; Bachurin S.O.; Molecular aspects of the pathogenesis and current approaches to pharmacological correction of Alzheimer\u2019s disease. Zh Nevrol Psikhiatr Im S S Korsakova 2015,115(6),103-114","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jconrel.2022.02.034","volume":"345","author":"Xi Y.","year":"2022","unstructured":"Xi Y.; Chen Y.; Jin Y.; Han G.; Song M.; Song T.; Shi Y.; Tao L.; Huang Z.; Zhou J.; Ding Y.; Zhang H.; Versatile nanomaterials for Alzheimer\u2019s disease: Pathogenesis inspired disease-modifying therapy. J Control Release 2022,345,38-61","journal-title":"J Control Release"},{"key":"ref=9","first-page":"32","volume":"1","author":"Jellinger K.A.","year":"2020","unstructured":"Jellinger K.A.; Neuropathology of the Alzheimer\u2019s continuum: an update. Free Neuropathol 2020,1,32-65","journal-title":"Free Neuropathol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.phrs.2017.11.021","volume":"129","author":"Bachurin S.O.","year":"2018","unstructured":"Bachurin S.O.; Gavrilova S.I.; Samsonova A.; Barreto G.E.; Aliev G.; Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention. Pharmacol Res 2018,129,216-226","journal-title":"Pharmacol Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.cbi.2019.05.020","volume":"308","author":"Makhaeva G.F.","year":"2019","unstructured":"Makhaeva G.F.; Shevtsova E.F.; Boltneva N.P.; Lushchekina S.V.; Kovaleva N.V.; Rudakova E.V.; Bachurin S.O.; Richardson R.J.; Overview of novel multifunctional agents based on conjugates of \u03b3-carbolines, carbazoles, tetrahydrocarbazoles, phenothiazines, and aminoadamantanes for treatment of Alzheimer\u2019s disease. Chem Biol Interact 2019,308,224-234","journal-title":"Chem Biol Interact"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"101303","DOI":"10.1016\/j.apmt.2021.101303","volume":"26","author":"Hinge N.S.","year":"2022","unstructured":"Hinge N.S.; Kathuria H.; Pandey M.M.; Engineering of structural and functional properties of nanotherapeutics and nanodiagnostics for intranasal brain targeting in Alzheimer\u2019s. Appl Mater Today 2022,26,101303-101335","journal-title":"Appl Mater Today"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnsyn.2020.00020","volume":"12","author":"Ord\u00f3\u00f1ez-Guti\u00e9rrez L.","year":"2020","unstructured":"Ord\u00f3\u00f1ez-Guti\u00e9rrez L.; Wandosell F.; Nanoliposomes as a therapeutic tool for Alzheimer\u2019s disease. Front Synaptic Neurosci 2020,12,20-29","journal-title":"Front Synaptic Neurosci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jconrel.2019.12.034","volume":"319","author":"Gopalan D.","year":"2020","unstructured":"Gopalan D.; Pandey A.; Udupa N.; Mutalik S.; Receptor specific, stimuli responsive and subcellular targeted approaches for effective therapy of Alzheimer: Role of surface engineered nanocarriers. J Control Release 2020,319,183-200","journal-title":"J Control Release"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/pharmaceutics14040835","volume":"14","author":"Poudel P.","year":"2022","unstructured":"Poudel P.; Park S.; Recent advances in the treatment of Alzheimer\u2019s disease using nanoparticle-based drug delivery systems. Pharmaceutics 2022,14(4),835-872","journal-title":"Pharmaceutics"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3390\/pharmaceutics13071042","volume":"13","author":"Cunha A.","year":"2021","unstructured":"Cunha A.; Gaubert A.; Latxague L.; Dehay B.; PLGA-based nanoparticles for neuroprotective drug delivery in neurodegenerative diseases. Pharmaceutics 2021,13(7),1042-1065","journal-title":"Pharmaceutics"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejpb.2019.12.014","volume":"148","author":"Akel H.","year":"2020","unstructured":"Akel H.; Ismail R.; Cs\u00f3ka I.; Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer\u2019s disease. Eur J Pharm Biopharm 2020,148,38-53","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.3390\/molecules26226786","volume":"26","author":"Gaynanova G.","year":"2021","unstructured":"Gaynanova G.; Vasileva L.; Kashapov R.; Kuznetsova D.; Kushnazarova R.; Tyryshkina A.; Vasilieva E.; Petrov K.; Zakharova L.; Sinyashin O.; Self-assembling drug formulations with tunable permeability and biodegradability. Molecules 2021,26(22),6786-6825","journal-title":"Molecules"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"7055","DOI":"10.3390\/ijms22137055","volume":"22","author":"Kashapov R.","year":"2021","unstructured":"Kashapov R.; Ibragimova A.; Pavlov R.; Gabdrakhmanov D.; Kashapova N.; Burilova E.; Zakharova L.; Sinyashin O.; Nanocarriers for biomedicine: from lipid formulations to inorganic and hybrid nanoparticles. Int J Mol Sci 2021,22(13),7055-7104","journal-title":"Int J Mol Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1070\/RCR5011","volume":"90","author":"Antipin I.S.","year":"2021","unstructured":"Antipin I.S.; Alfimov M.V.; Arslanov V.V.; Burilov V.A.; Vatsadze S.Z.; Voloshin Y.Z.; Volcho K.P.; Gorbatchuk V.V.; Gorbunova Y.G.; Gromov S.P.; Dudkin S.V.; Zaitsev S.Y.; Zakharova L.Y.; Ziganshin M.A.; Zolotukhina A.V.; Kalinina M.A.; Karakhanov E.A.; Kashapov R.R.; Koifman O.I.; Konovalov A.I.; Korenev V.S.; Maksimov A.L.; Mamardashvili N.Z.; Mamardashvili G.M.; Martynov A.G.; Mustafina A.R.; Nugmanov R.I.; Ovsyannikov A.S.; Padnya P.L.; Potapov A.S.; Selektor S.L.; Sokolov M.N.; Solovieva S.E.; Stoikov I.I.; Stuzhin P.A.; Suslov E.V.; Ushakov E.N.; Fedin V.P.; Fedorenko S.V.; Fedorova O.A.; Fedorov Y.V.; Chvalun S.N.; Tsivadze A.Y.; Shtykov S.N.; Shurpik D.N.; Shcherbina M.A.; Yakimova L.S.; Functional supramolecular systems: Design and applications. Russ Chem Rev 2021,90(8),895-1107","journal-title":"Russ Chem Rev"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"6961","DOI":"10.3390\/ijms21186961","volume":"21","author":"Kashapov R.","year":"2020","unstructured":"Kashapov R.; Gaynanova G.; Gabdrakhmanov D.; Kuznetsov D.; Pavlov R.; Petrov K.; Zakharova L.; Sinyashin O.; Self-assembly of amphiphilic compounds as a versatile tool for construction of nanoscale drug carriers. Int J Mol Sci 2020,21(18),6961-7007","journal-title":"Int J Mol Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jconrel.2022.05.056","volume":"348","author":"Ding H.","year":"2022","unstructured":"Ding H.; Tan P.; Fu S.; Tian X.; Zhang H.; Ma X.; Gu Z.; Luo K.; Preparation and application of pH-responsive drug delivery systems. J Control Release 2022,348,206-238","journal-title":"J Control Release"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jconrel.2016.11.025","volume":"245","author":"Wen M.M.","year":"2017","unstructured":"Wen M.M.; El-Salamouni N.S.; El-Refaie W.M.; Hazzah H.A.; Ali M.M.; Tosi G.; Farid R.M.; Blanco-Prieto M.J.; Billa N.; Hanafy A.S.; Nanotechnology-based drug delivery systems for Alzheimer\u2019s disease management: Technical, industrial, and clinical challenges. J Control Release 2017,245,95-107","journal-title":"J Control Release"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1212\/WNL.0000000000009058","volume":"94","author":"Ferreira D.","year":"2020","unstructured":"Ferreira D.; Nordberg A.; Westman E.; Biological subtypes of Alzheimer disease: A systematic review and meta- analysis. Neurology 2020,94,436-448","journal-title":"Neurology"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1212\/01.WNL.0000115115.98960.37","volume":"62","author":"Ingelsson M.","year":"2004","unstructured":"Ingelsson M.; Fukumoto H.; Newell K.L.; Growdon J.H.; Hedley-Whyte E.T.; Frosch M.P.; Albert M.S.; Hyman B.T.; Irizarry M.C.; Early A accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004,62(6),925-931","journal-title":"Neurology"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"Keren-Shaul H.","year":"2017","unstructured":"Keren-Shaul H.; Spinrad A.; Weiner A.; Matcovitch-Natan O.; Dvir-Szternfeld R.; Ulland T.K.; David E.; Baruch K.; Lara-Astaiso D.; Toth B.; Itzkovitz S.; Colonna M.; Schwartz M.; Amit I.; A Unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell 2017,169(7),1276-1290.e17","journal-title":"Cell"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1007\/s12035-020-01926-1","volume":"57","author":"Monzio Compagnoni G.","year":"2020","unstructured":"Monzio Compagnoni G.; Di Fonzo A.; Corti S.; Comi G.P.; Bresolin N.; Masliah E.; The role of mitochondria in neurodegenerative diseases: the lesson from Alzheimer\u2019s disease and Parkinson\u2019s disease. Mol Neurobiol 2020,57(7),2959-2980","journal-title":"Mol Neurobiol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nrn.2017.48","volume":"18","author":"Kisler K.","year":"2017","unstructured":"Kisler K.; Nelson A.R.; Montagne A.; Zlokovic B.V.; Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci 2017,18(7),419-434","journal-title":"Nat Rev Neurosci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","volume":"25","author":"Nation D.A.","year":"2019","unstructured":"Nation D.A.; Sweeney M.D.; Montagne A.; Sagare A.P.; D\u2019Orazio L.M.; Pachicano M.; Sepehrband F.; Nelson A.R.; Buennagel D.P.; Harrington M.G.; Benzinger T.L.S.; Fagan A.M.; Ringman J.M.; Schneider L.S.; Morris J.C.; Chui H.C.; Law M.; Toga A.W.; Zlokovic B.V.; Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med 2019,25(2),270-276","journal-title":"Nat Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"Heneka M.T.","year":"2015","unstructured":"Heneka M.T.; Carson M.J.; Khoury J.E.; Landreth G.E.; Brosseron F.; Feinstein D.L.; Jacobs A.H.; Wyss-Coray T.; Vitorica J.; Ransohoff R.M.; Herrup K.; Frautschy S.A.; Finsen B.; Brown G.C.; Verkhratsky A.; Yamanaka K.; Koistinaho J.; Latz E.; Halle A.; Petzold G.C.; Town T.; Morgan D.; Shinohara M.L.; Perry V.H.; Holmes C.; Bazan N.G.; Brooks D.J.; Hunot S.; Joseph B.; Deigendesch N.; Garaschuk O.; Boddeke E.; Dinarello C.A.; Breitner J.C.; Cole G.M.; Golenbock D.T.; Kummer M.P.; Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 2015,14(4),388-405","journal-title":"Lancet Neurol"},{"key":"ref=31","first-page":"361","volume":"8","author":"Sozio P.","year":"2012","unstructured":"Sozio P.; Cerasa L.S.; Marinelli L.; Di Stefano A.; Transdermal donepezil on the treatment of Alzheimer\u2019s disease. Neuropsychiatr Dis Treat 2012,8,361-368","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","volume":"235","author":"Saraiva C.","year":"2016","unstructured":"Saraiva C.; Pra\u00e7a C.; Ferreira R.; Santos T.; Ferreira L.; Bernardino L.; Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release 2016,235,34-47","journal-title":"J Control Release"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/10611860410001701706","volume":"12","author":"Visser C.C.","year":"2004","unstructured":"Visser C.C.; Stevanovi\u0107 S.; Heleen Voorwinden L.; Gaillard P.J.; Crommelin D.J.A.; Danhof M.; de Boer A.G.; Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro. J Drug Target 2004,12(3),145-150","journal-title":"J Drug Target"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1021\/mp3004308","volume":"10","author":"Ohtsuki S.","year":"2013","unstructured":"Ohtsuki S.; Ikeda C.; Uchida Y.; Sakamoto Y.; Miller F.; Glacial F.; Decleves X.; Scherrmann J.M.; Couraud P.O.; Kubo Y.; Tachikawa M.; Terasaki T.; Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC\/D3 as a human blood-brain barrier model. Mol Pharm 2013,10(1),289-296","journal-title":"Mol Pharm"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jconrel.2017.05.019","volume":"260","author":"Agrawal M.","year":"2017","unstructured":"Agrawal M.; Ajazuddin ; Tripathi D.K.; Saraf S.; Saraf S.; Antimisiaris S.G.; Mourtas S.; Hammarlund-Udenaes M.; Alexander A.; Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer\u2019s disease. J Control Release 2017,260,61-77","journal-title":"J Control Release"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1208\/s12248-008-9055-2","volume":"10","author":"Herv\u00e9 F.","year":"2008","unstructured":"Herv\u00e9 F.; Ghinea N.; Scherrmann J.M.; CNS delivery via adsorptive transcytosis. AAPS J 2008,10(3),455-472","journal-title":"AAPS J"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/cne.902420410","volume":"242","author":"Broadwell R.D.","year":"1985","unstructured":"Broadwell R.D.; Balin B.J.; Endocytic and exocytic pathways of the neuronal secretory process and trans synaptic transfer of wheat germ agglutinin-horseradish peroxidase in vivo. J Comp Neurol 1985,242(4),632-650","journal-title":"J Comp Neurol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijpharm.2005.01.043","volume":"295","author":"Lu W.","year":"2005","unstructured":"Lu W.; Tan Y.Z.; Hu K.L.; Jiang X.G.; Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier. Int J Pharm 2005,295(1-2),247-260","journal-title":"Int J Pharm"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"11878","DOI":"10.1158\/0008-5472.CAN-06-2354","volume":"66","author":"Lu W.","year":"2006","unstructured":"Lu W.; Sun Q.; Wan J.; She Z.; Jiang X.G.; Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res 2006,66(24),11878-11887","journal-title":"Cancer Res"},{"key":"ref=40","first-page":"R478","volume":"261","author":"Shimon-Hophy M.","year":"1991","unstructured":"Shimon-Hophy M.; Wadhwani K.C.; Chandrasekaran K.; Larson D.; Smith Q.R.; Rapoport S.I.; Regional blood-brain barrier transport of cationized bovine serum albumin in awake rats. Am J Physiol 1991,261(2 Pt 2),R478-R483","journal-title":"Am J Physiol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"119640","DOI":"10.1016\/j.ijpharm.2020.119640","volume":"587","author":"Pavlov R.V.","year":"2020","unstructured":"Pavlov R.V.; Gaynanova G.A.; Kuznetsova D.A.; Vasileva L.A.; Zueva I.V.; Sapunova A.S.; Buzyurova D.N.; Babaev V.M.; Voloshina A.D.; Lukashenko S.S.; Rizvanov I.K.; Petrov K.A.; Zakharova L.Y.; Sinyashin O.G.; Biomedical potentialities of cationic geminis as modulating agents of liposome in drug delivery across biological barriers and cellular uptake. Int J Pharm 2020,587,119640-119651","journal-title":"Int J Pharm"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ejpb.2008.08.021","volume":"71","author":"Ulbrich K.","year":"2009","unstructured":"Ulbrich K.; Hekmatara T.; Herbert E.; Kreuter J.; Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 2009,71(2),251-256","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.biomaterials.2007.09.024","volume":"29","author":"Huang R.","year":"2008","unstructured":"Huang R.; Ke W.; Liu Y.; Jiang C.; Pei Y.; The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials 2008,29(2),238-246","journal-title":"Biomaterials"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ddtec.2016.09.003","volume":"20","author":"Maussang D.","year":"2016","unstructured":"Maussang D.; Rip J.; van Kregten J.; van den Heuvel A.; van der Pol S.; van der Boom B.; Reijerkerk A.; Chen L.; de Boer M.; Gaillard P.; de Vries H.; Glutathione conjugation dose-dependently increases brain-specific liposomal drug delivery in vitro and in vivo. Drug Discov Today Technol 2016,20,59-69","journal-title":"Drug Discov Today Technol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","volume":"12","author":"Keller L.A.","year":"2022","unstructured":"Keller L.A.; Merkel O.; Popp A.; Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res 2022,12(4),735-757","journal-title":"Drug Deliv Transl Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","volume":"195","author":"Crowe T.P.","year":"2018","unstructured":"Crowe T.P.; Greenlee M.H.W.; Kanthasamy A.G.; Hsu W.H.; Mechanism of intranasal drug delivery directly to the brain. Life Sci 2018,195,44-52","journal-title":"Life Sci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"118635","DOI":"10.1016\/j.ijpharm.2019.118635","volume":"570","author":"Martins P.P.","year":"2019","unstructured":"Martins P.P.; Smyth H.D.C.; Cui Z.; Strategies to facilitate or block nose-to-brain drug delivery. Int J Pharm 2019,570,118635-118643","journal-title":"Int J Pharm"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2017.10.046","volume":"535","author":"Sala M.","year":"2018","unstructured":"Sala M.; Diab R.; Elaissari A.; Fessi H.; Lipid nanocarriers as skin drug delivery systems: Properties, mechanisms of skin interactions and medical applications. Int J Pharm 2018,535(1-2),1-17","journal-title":"Int J Pharm"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"11991","DOI":"10.3390\/ijms222111991","volume":"22","author":"Gomes A.","year":"2021","unstructured":"Gomes A.; Aguiar L.; Ferraz R.; Teixeira C.; Gomes P.; The emerging role of ionic liquid-based approaches for enhanced skin permeation of bioactive molecules: a snapshot of the past couple of years. Int J Mol Sci 2021,22(21),11991-12016","journal-title":"Int J Mol Sci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"646554","DOI":"10.3389\/fbioe.2021.646554","volume":"9","author":"Yu Y.Q.","year":"2021","unstructured":"Yu Y.Q.; Yang X.; Wu X.F.; Fan Y.B.; Enhancing permeation of drug molecules across the skin via delivery in nanocarriers: Novel strategies for effective transdermal applications. Front Bioeng Biotechnol 2021,9,646554-646570","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejpb.2008.11.001","volume":"71","author":"Knorr F.","year":"2009","unstructured":"Knorr F.; Lademann J.; Patzelt A.; Sterry W.; Blume-Peytavi U.; Vogt A.; Follicular transport route - Research progress and future perspectives. Eur J Pharm Biopharm 2009,71(2),173-180","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.addr.2021.01.019","volume":"174","author":"Antimisiaris S.G.","year":"2021","unstructured":"Antimisiaris S.G.; Marazioti A.; Kannavou M.; Natsaridis E.; Gkartziou F.; Kogkos G.; Mourtas S.; Overcoming barriers by local drug delivery with liposomes. Adv Drug Deliv Rev 2021,174,53-86","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/bios8020031","volume":"8","author":"Lu F.","year":"2018","unstructured":"Lu F.; Wang C.; Zhao R.; Du L.; Fang Z.; Guo X.; Zhao Z.; Review of stratum corneum impedance measurement in non-invasive penetration application. Biosensors (Basel) 2018,8(2),31-50","journal-title":"Biosensors (Basel)"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"901940","DOI":"10.1155\/2012\/901940","volume":"2012","author":"Hogan M.B.","year":"2012","unstructured":"Hogan M.B.; Peele K.; Wilson N.W.; Skin barrier function and its importance at the start of the atopic march. J Allergy (Cairo) 2012,2012,901940","journal-title":"J Allergy (Cairo)"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/1523-1747.ep12462252","volume":"90","author":"Warner R.R.","year":"1988","unstructured":"Warner R.R.; Myers M.C.; Taylor D.A.; Electron probe analysis of human skin: determination of the water concentration profile. J Invest Dermatol 1988,90(2),218-224","journal-title":"J Invest Dermatol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"103111","DOI":"10.1016\/j.jddst.2022.103111","volume":"69","author":"Villanueva-Mart\u00ednez A.","year":"2022","unstructured":"Villanueva-Mart\u00ednez A.; Merino V.; Ganem-Rondero A.; Transdermal formulations and strategies for the treatment of osteoporosis. J Drug Deliv Sci Technol 2022,69,103111-103131","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"960","DOI":"10.3390\/pharmaceutics13070960","volume":"13","author":"Neupane R.","year":"2021","unstructured":"Neupane R.; Boddu S.H.S.; Abou-Dahech M.S.; Bachu R.D.; Terrero D.; Babu R.J.; Tiwari A.K.; Transdermal delivery of chemotherapeutics: Strategies, requirements, and opportunities. Pharmaceutics 2021,13(7),960-991","journal-title":"Pharmaceutics"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"103110","DOI":"10.1016\/j.jddst.2022.103110","volume":"68","author":"De Oliveira T.C.","year":"2022","unstructured":"De Oliveira T.C.; Tavares M.E.V.; Soares-Sobrinho J.L.; Chaves L.L.; The role of nanocarriers for transdermal application targeted to lymphatic drug delivery: Opportunities and challenges. J Drug Deliv Sci Technol 2022,68,103110-103118","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1021\/acs.molpharmaceut.1c00290","volume":"18","author":"Zhao Z.Q.","year":"2021","unstructured":"Zhao Z.Q.; Chen B.Z.; Zhang X.P.; Zheng H.; Guo X.D.; An update on the routes for the delivery of donepezil. Mol Pharm 2021,18(7),2482-2494","journal-title":"Mol Pharm"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"113957","DOI":"10.1016\/j.addr.2021.113957","volume":"177","author":"Abdelkader H.","year":"2021","unstructured":"Abdelkader H.; Fathalla Z.; Seyfoddin A.; Farahani M.; Thrimawithana T.; Allahham A.; Alani A.W.G.; Al-Kinani A.A.; Alany R.G.; Polymeric long-acting drug delivery systems (LADDS) for treatment of chronic diseases: Inserts, patches, wafers, and implants. Adv Drug Deliv Rev 2021,177,113957-113977","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3390\/pharmaceutics13081132","volume":"13","author":"Yadav P.R.","year":"2021","unstructured":"Yadav P.R.; Munni M.N.; Campbell L.; Mostofa G.; Dobson L.; Shittu M.; Pattanayek S.K.; Uddin M.J.; Das D.B.; J.; Das, D.B. Translation of polymeric microneedles for treatment of human diseases: recent trends, progress, and challenges. Pharmaceutics 2021,13(8),1132-1176","journal-title":"Pharmaceutics"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"102549","DOI":"10.1016\/j.jddst.2021.102549","volume":"63","author":"Sutthapitaksakul L.","year":"2021","unstructured":"Sutthapitaksakul L.; Dass C.R.; Sriamornsak P.; Donepezil\u2014an updated review of challenges in dosage form design. J Drug Deliv Sci Technol 2021,63,102549-102560","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/2042098617750555","volume":"9","author":"Khoury R.","year":"2018","unstructured":"Khoury R.; Rajamanickam J.; Grossberg G.T.; An update on the safety of current therapies for Alzheimer\u2019s disease: Focus on rivastigmine. Ther Adv Drug Saf 2018,9(3),171-178","journal-title":"Ther Adv Drug Saf"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1080\/1061186X.2016.1245310","volume":"25","author":"Ita K.","year":"2017","unstructured":"Ita K.; Recent trends in the transdermal delivery of therapeutic agents used for the management of neurodegenerative diseases. J Drug Target 2017,25(5),406-419","journal-title":"J Drug Target"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/10837450.2016.1189937","volume":"22","author":"Govender T.","year":"2017","unstructured":"Govender T.; Choonara Y.E.; Kumar P.; Bijukumar D.; du Toit L.C.; Modi G.; Naidoo D.; Pillay V.; Implantable and transdermal polymeric drug delivery technologies for the treatment of central nervous system disorders. Pharm Dev Technol 2017,22(4),476-486","journal-title":"Pharm Dev Technol"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/0253-7613.208143","volume":"49","author":"Nguyen T.T.","year":"2017","unstructured":"Nguyen T.T.; Giau V.V.; Vo T.K.; Current advances in transdermal delivery of drugs for Alzheimer\u2019s disease. Indian J Pharmacol 2017,49(2),145-154","journal-title":"Indian J Pharmacol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ejpb.2019.04.008","volume":"139","author":"Ameen D.","year":"2019","unstructured":"Ameen D.; Michniak-Kohn B.; Development and in vitro evaluation of pressure sensitive adhesive patch for the transdermal delivery of galantamine: Effect of penetration enhancers and crystallization inhibition. Eur J Pharm Biopharm 2019,139,262-271","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ijpharm.2013.02.040","volume":"447","author":"Lane M.E.","year":"2013","unstructured":"Lane M.E.; Skin penetration enhancers. Int J Pharm 2013,447(1-2),12-21","journal-title":"Int J Pharm"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00396-020-04621-8","volume":"298","author":"Georgieva D.","year":"2020","unstructured":"Georgieva D.; Ivanova-Mileva K.; Ivanova S.; Kostova B.; Rachev D.; Christova D.; Thermoresponsive poly(N-isopropylacrylamide) copolymer networks for galantamine hydrobromide delivery. Colloid Polym Sci 2020,298(4-5),377-384","journal-title":"Colloid Polym Sci"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"940","DOI":"10.33263\/BRIAC121.940960","volume":"12","author":"Dan S.","year":"2021","unstructured":"Dan S.; Sharma D.; Rastogi K.; Shaloo; Ojha, H.; Pathak, M.; Singhal, R. Therapeutic and diagnostic applications of nanocomposites in the treatment Alzheimer\u2019s disease studies. Biointerface Res Appl Chem 2021,12(1),940-960","journal-title":"Biointerface Res Appl Chem"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1080\/08982104.2020.1787440","volume":"31","author":"Salimi A.","year":"2021","unstructured":"Salimi A.; Ghobadian H.; Sharif Makhmalzadeh B.; Dermal pharmacokinetics of rivastigmine-loaded liposomes: An ex vivo - in vivo correlation study. J Liposome Res 2021,31(3),246-254","journal-title":"J Liposome Res"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"85","DOI":"10.22159\/ijap.2017v9i6.22354","volume":"9","author":"Ravi G.","year":"2017","unstructured":"Ravi G.; Gupta N.V.; Development and evaluation of transdermal film containing solid lipid nanoparticles of rivastigmine tartrate. Int J Appl Pharmaceut 2017,9(6),85-90","journal-title":"Int J Appl Pharmaceut"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.colsurfb.2019.02.007","volume":"177","author":"Mendes I.T.","year":"2019","unstructured":"Mendes I.T.; Ruela A.L.M.; Carvalho F.C.; Freitas J.T.J.; Bonfilio R.; Pereira G.R.; Development and characterization of nanostructured lipid carrier-based gels for the transdermal delivery of donepezil. Colloids Surf B Biointerfaces 2019,177,274-281","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ijbiomac.2019.04.191","volume":"134","author":"Kodoth A.K.","year":"2019","unstructured":"Kodoth A.K.; Ghate V.M.; Lewis S.A.; Prakash B.; Badalamoole V.; Pectin-based silver nanocomposite film for transdermal delivery of Donepezil. Int J Biol Macromol 2019,134,269-279","journal-title":"Int J Biol Macromol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ejpb.2016.06.006","volume":"105","author":"Kim J.Y.","year":"2016","unstructured":"Kim J.Y.; Han M.R.; Kim Y.H.; Shin S.W.; Nam S.Y.; Park J.H.; Tip-loaded dissolving microneedles for transdermal delivery of donepezil hydrochloride for treatment of Alzheimer\u2019s disease. Eur J Pharm Biopharm 2016,105,148-155","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/pharmaceutics14010005","volume":"14","author":"Rehman N.U.","year":"2021","unstructured":"Rehman N.U.; Song C.; Kim J.; Noh I.; Rhee Y.S.; Chung H.J.; Pharmacokinetic evaluation of a novel donepezil-loaded dissolving microneedle patch in rats. Pharmaceutics 2021,14(1),5-19","journal-title":"Pharmaceutics"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejpb.2020.12.006","volume":"159","author":"Vora L.K.","year":"2021","unstructured":"Vora L.K.; Moffatt K.; Tekko I.A.; Paredes A.J.; Volpe-Zanutto F.; Mishra D.; Peng K.; Raj Singh Thakur R.; Donnelly R.F.; Microneedle array systems for long-acting drug delivery. Eur J Pharm Biopharm 2021,159,44-76","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"100124","DOI":"10.1016\/j.medidd.2022.100124","volume":"14","author":"Shi C.","year":"2022","unstructured":"Shi C.; Yang D.; Zhao Y.; Wen T.; Zhao W.; Hu P.; Huang Z.; Quan G.; Wu C.; Pan X.; The spatial-dimensional and temporal-dimensional fate of nanocarrier-loaded dissolving microneedles with different lengths of needles. Med Drug Discov 2022,14,100124-100133","journal-title":"Med Drug Discov"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijbiomac.2022.02.127","volume":"207","author":"Don T.M.","year":"2022","unstructured":"Don T.M.; Chen M.; Lee I.C.; Huang Y.C.; Preparation and characterization of fast dissolving ulvan microneedles for transdermal drug delivery system. Int J Biol Macromol 2022,207,90-99","journal-title":"Int J Biol Macromol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"106202","DOI":"10.1016\/j.ejps.2022.106202","volume":"174","author":"Al-Rawi N.N.","year":"2022","unstructured":"Al-Rawi N.N.; Rawas-Qalaji M.; Dissolving microneedles with antibacterial functionalities: A systematic review of laboratory studies. Eur J Pharm Sci 2022,174,106202-106216","journal-title":"Eur J Pharm Sci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"719905","DOI":"10.3389\/fphar.2021.719905","volume":"12","author":"Zhang N.","year":"2021","unstructured":"Zhang N.; Zhou X.; Liu L.; Zhao L.; Xie H.; Yang Z.; Dissolving polymer microneedles for transdermal delivery of insulin. Front Pharmacol 2021,12,719905-719914","journal-title":"Front Pharmacol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jconrel.2021.10.001","volume":"339","author":"Peng K.","year":"2021","unstructured":"Peng K.; Vora L.K.; Tekko I.A.; Permana A.D.; Dom\u00ednguez-Robles J.; Ramadon D.; Chambers P.; McCarthy H.O.; Larra\u00f1eta E.; Donnelly R.F.; Dissolving microneedle patches loaded with amphotericin B microparticles for localised and sustained intradermal delivery: Potential for enhanced treatment of cutaneous fungal infections. J Control Release 2021,339,361-380","journal-title":"J Control Release"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1080\/10717544.2020.1797240","volume":"27","author":"Yan Q.","year":"2020","unstructured":"Yan Q.; Wang W.; Weng J.; Zhang Z.; Yin L.; Yang Q.; Guo F.; Wang X.; Chen F.; Yang G.; Dissolving microneedles for transdermal delivery of huperzine A for the treatment of Alzheimer\u2019s disease. Drug Deliv 2020,27(1),1147-1155","journal-title":"Drug Deliv"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"149","DOI":"10.7324\/JAPS.2020.103019","volume":"10","author":"Agrawal S.","year":"2020","unstructured":"Agrawal S.; Gandhi S.N.; Gurjar P.; Saraswathy N.; Microneedles: An advancement to transdermal drug delivery system approach. J Appl Pharm Sci 2020,10(3),149-159","journal-title":"J Appl Pharm Sci"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"112308","DOI":"10.1016\/j.molliq.2019.112308","volume":"300","author":"Wu H.","year":"2020","unstructured":"Wu H.; Fang F.; Zheng L.; Ji W.; Qi M.; Hong M.; Ren G.; Ionic liquid form of donepezil: Preparation, characterization and formulation development. J Mol Liq 2020,300,112308-112318","journal-title":"J Mol Liq"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/pharmaceutics14010205","volume":"14","author":"Dinh L.","year":"2022","unstructured":"Dinh L.; Lee S.; Abuzar S.M.; Park H.; Hwang S.J.; Hwang, Formulation, preparation, characterization, and evaluation of dicarboxylic ionic liquid donepezil transdermal patches. Pharmaceutics 2022,14(1),205-224","journal-title":"Pharmaceutics"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"105774","DOI":"10.1016\/j.ejps.2021.105774","volume":"161","author":"Cai Y.","year":"2021","unstructured":"Cai Y.; Tian Q.; Liu C.; Fang L.; Development of long-acting rivastigmine drug-in-adhesive patch utilizing ion- pair strategy and characterization of controlled release mechanism. Eur J Pharm Sci 2021,161,105774-105783","journal-title":"Eur J Pharm Sci"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"8319","DOI":"10.3390\/ijms22158319","volume":"22","author":"Sguizzato M.","year":"2021","unstructured":"Sguizzato M.; Esposito E.; Cortesi R.; Lipid-based nanosystems as a tool to overcome skin barrier. Int J Mol Sci 2021,22(15),8319-8334","journal-title":"Int J Mol Sci"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.3109\/10717544.2013.846433","volume":"22","author":"Moghaddam A.A.","year":"2015","unstructured":"Moghaddam A.A.; Aqil M.; Ahmad F.J.; Ali M.M.; Sultana Y.; Ali A.; Nanoethosomes mediated transdermal delivery of vinpocetine for management of Alzheimer\u2019s disease. Drug Deliv 2015,22(8),1018-1026","journal-title":"Drug Deliv"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1208\/s12249-012-9767-6","volume":"13","author":"Shi J.","year":"2012","unstructured":"Shi J.; Wang Y.; Luo G.; Ligustrazine phosphate ethosomes for treatment of Alzheimer\u2019s disease, in vitro and in animal model studies. AAPS PharmSciTech 2012,13(2),485-492","journal-title":"AAPS PharmSciTech"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000501364","volume":"9","author":"Ueda K.","year":"2019","unstructured":"Ueda K.; Katayama S.; Arai T.; Furuta N.; Ikebe S.; Ishida Y.; Kanaya K.; Ouma S.; Sakurai H.; Sugitani M.; Takahashi M.; Tanaka T.; Tsuno N.; Wakutani Y.; Shekhawat A.; Das Gupta A.; Kiyose K.; Toriyama K.; Nakamura Y.; Efficacy, safety, and tolerability of switching from oral cholinesterase inhibitors to rivastigmine transdermal patch with 1-step titration in patients with mild to moderate Alzheimer\u2019s disease: A 24-week, open-label, multicenter study in Japan. Dement Geriatr Cogn Disord Extra 2019,9(2),302-318","journal-title":"Dement Geriatr Cogn Disord Extra"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1089\/jwh.2017.6420","volume":"27","author":"Colombo D.","year":"2018","unstructured":"Colombo D.; Caltagirone C.; Padovani A.; Sorbi S.; Spalletta G.; Simoni L.; Ori A.; Zagni E.; Gender differences in neuropsychiatric symptoms in mild to moderate Alzheimer\u2019s disease patients undergoing switch of cholinesterase inhibitors: A Post Hoc Analysis of the EVOLUTION Study. J Womens Health (Larchmt) 2018,27(11),1368-1377","journal-title":"J Womens Health (Larchmt)"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.bbamem.2016.02.028","volume":"1858","author":"Ramezanpour M.","year":"2016","unstructured":"Ramezanpour M.; Leung S.S.W.; Delgado-Magnero K.H.; Bashe B.Y.M.; Thewalt J.; Tieleman D.P.; Computational and experimental approaches for investigating nanoparticle-based drug delivery systems. Biochim Biophys Acta 2016,1858,1688-1709","journal-title":"Biochim Biophys Acta"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"112785","DOI":"10.1016\/j.colsurfb.2022.112785","volume":"218","author":"Mehta S.","year":"2022","unstructured":"Mehta S.; Dumoga S.; Malhotra S.; Singh N.; Comparative analysis of PEG-liposomes and RBCs-derived nanovesicles for anti-tumor therapy. Colloids Surf B Biointerfaces 2022,218,112785-112790","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1124\/dmd.121.000568","volume":"50","author":"Yin L.","year":"2022","unstructured":"Yin L.; Pang Y.; Shan L.; Gu J.; The in vivo Pharmacokinetics of block copolymers containing polyethylene glycol used in nanocarrier drug delivery systems. Drug Metab Dispos 2022,50(6),827-836","journal-title":"Drug Metab Dispos"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1080\/10717544.2021.1889717","volume":"28","author":"Jiang T.","year":"2021","unstructured":"Jiang T.; Ma S.; Shen Y.; Li Y.; Pan R.; Xing H.; Topical anesthetic and pain relief using penetration enhancer and transcriptional transactivator peptide multi-decorated nanostructured lipid carriers. Drug Deliv 2021,28(1),478-486","journal-title":"Drug Deliv"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"869269","DOI":"10.1155\/2014\/869269","volume":"2014","author":"Upadhyay R.K.","year":"2014","unstructured":"Upadhyay R.K.; Drug delivery systems, CNS protection, and the blood brain barrier. BioMed Res Int 2014,2014,869269","journal-title":"BioMed Res Int"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"121780","DOI":"10.1016\/j.ijpharm.2022.121780","volume":"621","author":"Moya E.L.J.","year":"2022","unstructured":"Moya E.L.J.; Lombardo S.M.; Vandenhaute E.; Schneider M.; Mysiorek C.; T\u00fcreli A.E.; Kanda T.; Shimizu F.; Sano Y.; Maubon N.; Gosselet F.; G\u00fcnday-T\u00fcreli N.; Dehouck M.P.; Interaction of surfactant coated PLGA nanoparticles with in vitro human brain-like endothelial cells. Int J Pharm 2022,621,121780-121792","journal-title":"Int J Pharm"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"15330338221080974","DOI":"10.1177\/15330338221080974","volume":"21","author":"Mehrabian A.","year":"2022","unstructured":"Mehrabian A.; Mashreghi M.; Dadpour S.; Badiee A.; Arabi L.; Hoda Alavizadeh S.; Alia Moosavian S.; Reza Jaafari M.; Nanocarriers call the last shot in the treatment of brain cancers. Technol Cancer Res Treat 2022,21,15330338221080974","journal-title":"Technol Cancer Res Treat"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1021\/acschemneuro.1c00022","volume":"12","author":"K C S.","year":"2021","unstructured":"K C S.; Kakoty V.; Krishna K.V.; Dubey S.K.; Chitkara D.; Taliyan R.; Neuroprotective efficacy of co-encapsulated rosiglitazone and vorinostat nanoparticle on streptozotocin induced mice model of Alzheimer\u2019s disease. ACS Chem Neurosci 2021,12(9),1528-1541","journal-title":"ACS Chem Neurosci"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/14740338.2020.1721456","volume":"19","author":"Haake A.","year":"2020","unstructured":"Haake A.; Nguyen K.; Friedman L.; Chakkamparambil B.; Grossberg G.T.; An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer\u2019s disease. Expert Opin Drug Saf 2020,19(2),147-157","journal-title":"Expert Opin Drug Saf"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/17425255.2020.1779700","volume":"16","author":"Cacabelos R.","year":"2020","unstructured":"Cacabelos R.; Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer\u2019s disease. Expert Opin Drug Metab Toxicol 2020,16(8),673-701","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1021\/acschemneuro.9b00343","volume":"10","author":"Krishna K.V.","year":"2019","unstructured":"Krishna K.V.; Wadhwa G.; Alexander A.; Kanojia N.; Saha R.N.; Kukreti R.; Singhvi G.; Dubey S.K.; Design and biological evaluation of lipoprotein-based donepezil nanocarrier for enhanced brain uptake through oral delivery. ACS Chem Neurosci 2019,10(9),4124-4135","journal-title":"ACS Chem Neurosci"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jcis.2015.10.057","volume":"463","author":"Neves A.R.","year":"2016","unstructured":"Neves A.R.; Queiroz J.F.; Costa Lima S.A.; Figueiredo F.; Fernandes R.; Reis S.; Cellular uptake and transcytosis of lipid-based nanoparticles across the intestinal barrier: Relevance for oral drug delivery. J Colloid Interface Sci 2016,463,258-265","journal-title":"J Colloid Interface Sci"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3390\/ijms17071171","volume":"17","author":"Liu W.","year":"2016","unstructured":"Liu W.; Pan H.; Zhang C.; Zhao L.; Zhao R.; Zhu Y.; Pan W.; Developments in methods for measuring the intestinal absorption of nanoparticle-bound drugs. Int J Mol Sci 2016,17(7),1171-1190","journal-title":"Int J Mol Sci"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.toxrep.2019.04.004","volume":"6","author":"Ghosh S.","year":"2019","unstructured":"Ghosh S.; Ghosh S.; Sil P.C.; Role of nanostructures in improvising oral medicine. Toxicol Rep 2019,6,358-368","journal-title":"Toxicol Rep"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"77","DOI":"10.17116\/jnevro20161168177-87","volume":"116","author":"Bachurin S.O.","year":"2016","unstructured":"Bachurin S.O.; A review of drugs for treatment of Alzheimer\u2019s disease in clinical trials: main trends. Zh Nevrol Psikhiatr Im S S Korsakova 2016,116(8),77-87","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/02699052.2022.2034962","volume":"36","author":"Florentino S.A.","year":"2022","unstructured":"Florentino S.A.; Bawany M.H.; Ma H.M.; Acetylcholinesterase inhibitors to enhance recovery from traumatic brain injury: a comprehensive review and case series. Brain Inj 2022,36(4),441-454","journal-title":"Brain Inj"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/B978-0-12-816200-2.00006-2","author":"Charoo N.A.","year":"2019","unstructured":"Charoo N.A.; Rahman Z.; Khan M.A.; Nanoparticles for Improvement in Oral Bioavailability. Nanoarchitectonics in Biomedicine 2019,371-410","journal-title":"Nanoarchitectonics in Biomedicine"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jconrel.2020.05.044","volume":"325","author":"Wilson B.","year":"2020","unstructured":"Wilson B.; Geetha K.M.; Neurotherapeutic applications of nanomedicine for treating Alzheimer\u2019s disease. J Control Release 2020,325,25-37","journal-title":"J Control Release"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.3390\/ijms21093248","volume":"21","author":"Markovic M.","year":"2020","unstructured":"Markovic M.; Ben-Shabat S.; Aponick A.; Zimmermann E.M.; Dahan A.; Lipids and lipid-processing pathways in drug delivery and therapeutics. Int J Mol Sci 2020,21(9),3248-3262","journal-title":"Int J Mol Sci"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.3390\/pharmaceutics13101635","volume":"13","author":"Abbas H.","year":"2021","unstructured":"Abbas H.; Gad H.A.; Khattab M.A.; Mansour M.; The tragedy of Alzheimer\u2019s disease: towards better management via resveratrol-loaded oral bilosomes. Pharmaceutics 2021,13(10),1635-1657","journal-title":"Pharmaceutics"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.4103\/1673-5374.327328","volume":"17","author":"Shukla S.","year":"2022","unstructured":"Shukla S.; Hernandez C.; Liposome based drug delivery as a potential treatment option for Alzheimer\u2019s disease. Neural Regen Res 2022,17(6),1190-1198","journal-title":"Neural Regen Res"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s13534-021-00198-5","volume":"11","author":"Seo M.W.","year":"2021","unstructured":"Seo M.W.; Park T.E.; Recent advances with liposomes as drug carriers for treatment of neurodegenerative diseases. Biomed Eng Lett 2021,11(3),211-216","journal-title":"Biomed Eng Lett"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1208\/s12249-021-02072-0","volume":"22","author":"Saka R.","year":"2021","unstructured":"Saka R.; Chella N.; Khan W.; Development of imatinib mesylate-loaded liposomes for nose to brain delivery: In vitro and in vivo evaluation. AAPS PharmSciTech 2021,22(5),192","journal-title":"AAPS PharmSciTech"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1208\/s12248-021-00648-z","volume":"23","author":"Juhairiyah F.","year":"2021","unstructured":"Juhairiyah F.; de Lange E.C.M.; Understanding drug delivery to the brain using liposome-based strategies: Studies that provide mechanistic insights are essential. AAPS J 2021,23(6),114-129","journal-title":"AAPS J"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.msec.2013.10.038","volume":"35","author":"Shah U.","year":"2014","unstructured":"Shah U.; Joshi G.; Sawant K.; Improvement in antihypertensive and antianginal effects of felodipine by enhanced absorption from PLGA nanoparticles optimized by factorial design. Mater Sci Eng C 2014,35,153-163","journal-title":"Mater Sci Eng C"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.colsurfb.2015.02.043","volume":"128","author":"Tariq M.","year":"2015","unstructured":"Tariq M.; Alam M.A.; Singh A.T.; Iqbal Z.; Panda A.K.; Talegaonkar S.; Biodegradable polymeric nanoparticles for oral delivery of epirubicin: In vitro, ex vivo, and in vivo investigations. Colloids Surf B Biointerfaces 2015,128,448-456","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejps.2014.04.014","volume":"60","author":"Joshi G.","year":"2014","unstructured":"Joshi G.; Kumar A.; Sawant K.; Enhanced bioavailability and intestinal uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery. Eur J Pharm Sci 2014,60,80-89","journal-title":"Eur J Pharm Sci"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12951-018-0356-z","volume":"16","author":"S\u00e1nchez-L\u00f3pez E.","year":"2018","unstructured":"S\u00e1nchez-L\u00f3pez E.; Ettcheto M.; Egea M.A.; Espina M.; Cano A.; Calpena A.C.; Camins A.; Carmona N.; Silva A.M.; Souto E.B.; Garc\u00eda M.L.; Memantine loaded PLGA PEGylated nanoparticles for Alzheimer\u2019s disease: In vitro and in vivo characterization. J Nanobiotechnol 2018,16(1),32-47","journal-title":"J Nanobiotechnol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1021\/acschemneuro.0c00430","volume":"11","author":"Krishna K.V.","year":"2020","unstructured":"Krishna K.V.; Saha R.N.; Dubey S.K.; Biophysical, biochemical, and behavioral implications of ApoE3 conjugated donepezil nanomedicine in a A\u03b2 induced Alzheimer\u2019s disease rat model. ACS Chem Neurosci 2020,11(24),4139-4151","journal-title":"ACS Chem Neurosci"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"878201","DOI":"10.3389\/fimmu.2022.878201","volume":"13","author":"Bartolom\u00e9 F.","year":"2022","unstructured":"Bartolom\u00e9 F.; Rosa L.; Valenti P.; Lopera F.; Hern\u00e1ndez-Gallego J.; Cantero J.L.; Orive G.; Carro E.; Lactoferrin as immune-enhancement strategy for SARS-CoV-2 infection in Alzheimer\u2019s disease patients. Front Immunol 2022,13,878201-878212","journal-title":"Front Immunol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ijbiomac.2020.06.058","volume":"162","author":"Agwa M.M.","year":"2020","unstructured":"Agwa M.M.; Abdelmonsif D.A.; Khattab S.N.; Sabra S.; Self-assembled lactoferrin-conjugated linoleic acid micelles as an orally active targeted nanoplatform for Alzheimer\u2019s disease. Int J Biol Macromol 2020,162,246-261","journal-title":"Int J Biol Macromol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1194\/jlr.M079400","volume":"59","author":"Monaco A.","year":"2018","unstructured":"Monaco A.; Ferrandino I.; Boscaino F.; Cocca E.; Cigliano L.; Maurano F.; Luongo D.; Spagnuolo M.S.; Rossi M.; Bergamo P.; Conjugated linoleic acid prevents age-dependent neurodegeneration in a mouse model of neuropsychiatric lupus via the activation of an adaptive response. J Lipid Res 2018,59(1),48-57","journal-title":"J Lipid Res"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijpharm.2015.03.001","volume":"485","author":"Laserra S.","year":"2015","unstructured":"Laserra S.; Basit A.; Sozio P.; Marinelli L.; Fornasari E.; Cacciatore I.; Ciulla M.; T\u00fcrkez H.; Geyikoglu F.; Di Stefano A.; Solid lipid nanoparticles loaded with lipoyl-memantine codrug: Preparation and characterization. Int J Pharm 2015,485(1-2),183-191","journal-title":"Int J Pharm"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.3109\/10717544.2015.1089956","volume":"23","author":"Misra S.","year":"2016","unstructured":"Misra S.; Chopra K.; Sinha V.R.; Medhi B.; Galantamine-loaded solid-lipid nanoparticles for enhanced brain delivery: Preparation, characterization, in vitro and in vivo evaluations. Drug Deliv 2016,23(4),1434-1443","journal-title":"Drug Deliv"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s10924-020-01937-y","volume":"29","author":"AnjiReddy K.","year":"2021","unstructured":"AnjiReddy K.; Karpagam S.; In vitro and in vivo evaluation of oral disintegrating nanofiber and thin-film contains hyperbranched chitosan\/donepezil for active drug delivery. J Polym Environ 2021,29(3),922-936","journal-title":"J Polym Environ"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev.pharmtox.47.120505.105237","volume":"47","author":"de Boer A.G.","year":"2007","unstructured":"de Boer A.G.; Gaillard P.J.; Drug targeting to the brain. Annu Rev Pharmacol Toxicol 2007,47(1),323-355","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"634","DOI":"10.52142\/omujecm.38.4.42","volume":"38","author":"Chougle S.","year":"2021","unstructured":"Chougle S.; Kumar D.; Khan A.; Zehra S.; Ali\u0307 A.; Treatment of Alzheimer\u2019s disease by natural products. J Exp Clin Med 2021,38(4),634-644","journal-title":"J Exp Clin Med"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"119990","DOI":"10.1016\/j.lfs.2021.119990","volume":"285","author":"Raju M.","year":"2021","unstructured":"Raju M.; Kunde S.S.; Auti S.T.; Kulkarni Y.A.; Wairkar S.; Berberine loaded nanostructured lipid carrier for Alzheimer\u2019s disease: Design, statistical optimization and enhanced in vivo performance. Life Sci 2021,285,119990-119996","journal-title":"Life Sci"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"101201","DOI":"10.1016\/j.jddst.2019.101201","volume":"53","author":"Sayed N.","year":"2019","unstructured":"Sayed N.; Khurana A.; Godugu C.; Pharmaceutical perspective on the translational hurdles of phytoconstituents and strategies to overcome. J Drug Deliv Sci Technol 2019,53,101201-101218","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"hzs003","DOI":"10.1093\/biohorizons\/hzs003","volume":"5","author":"Durham B.","year":"2012","unstructured":"Durham B.; Novel histone deacetylase (HDAC) inhibitors with improved selectivity for HDAC2 and 3 protect against neural cell death. Biosci Horiz 2012,5,hzs003","journal-title":"Biosci Horiz"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"11500","DOI":"10.1523\/JNEUROSCI.3203-08.2008","volume":"28","author":"Green K.N.","year":"2008","unstructured":"Green K.N.; Steffan J.S.; Martinez-Coria H.; Sun X.; Schreiber S.S.; Thompson L.M.; LaFerla F.M.; Nicotinamide restores cognition in Alzheimer\u2019s disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci 2008,28(45),11500-11510","journal-title":"J Neurosci"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40199-018-0221-5","volume":"26","author":"Vakilinezhad M.A.","year":"2018","unstructured":"Vakilinezhad M.A.; Amini A.; Akbari Javar H.; Baha\u2019addini Beigi Zarandi B.F.; Montaseri H.; Dinarvand R.; Nicotinamide loaded functionalized solid lipid nanoparticles improves cognition in Alzheimer\u2019s disease animal model by reducing Tau hyperphosphorylation. Daru 2018,26(2),165-177","journal-title":"Daru"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"113100","DOI":"10.1016\/j.bbr.2020.113100","volume":"402","author":"Labban S.","year":"2021","unstructured":"Labban S.; Alghamdi B.S.; Alshehri F.S.; Kurdi M.; Effects of melatonin and resveratrol on recognition memory and passive avoidance performance in a mouse model of Alzheimer\u2019s disease. Behav Brain Res 2021,402,113100-113108","journal-title":"Behav Brain Res"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.neurobiolaging.2020.04.012","volume":"94","author":"Al-Edresi S.","year":"2020","unstructured":"Al-Edresi S.; Alsalahat I.; Freeman S.; Aojula H.; Penny J.; Resveratrol-mediated cleavage of amyloid \u03b2 peptide: Potential relevance to Alzheimer\u2019s disease. Neurobiol Aging 2020,94,24-33","journal-title":"Neurobiol Aging"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jare.2021.03.012","volume":"35","author":"Qu C.","year":"2022","unstructured":"Qu C.; Li Q.P.; Su Z.R.; Ip S.P.; Yuan Q.J.; Xie Y.L.; Xu Q.Q.; Yang W.; Huang Y.F.; Xian Y.F.; Lin Z.X.; Nano-Honokiol ameliorates the cognitive deficits in TgCRND8 mice of Alzheimer\u2019s disease via inhibiting neuropathology and modulating gut microbiota. J Adv Res 2022,35,231-243","journal-title":"J Adv Res"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.phrs.2017.08.004","volume":"124","author":"Serafini M.M.","year":"2017","unstructured":"Serafini M.M.; Catanzaro M.; Rosini M.; Racchi M.; Lanni C.; Curcumin in Alzheimer\u2019s disease: Can we think to new strategies and perspectives for this molecule? Pharmacol Res 2017,124,146-155","journal-title":"Pharmacol Res"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"FSO677","DOI":"10.2144\/fsoa-2020-0131","volume":"7","author":"Yusuf H.","year":"2021","unstructured":"Yusuf H.; Rahmawati R.A.; Syamsur Rijal M.A.; Isadiartuti D.; Curcumin micelles entrapped in eudragit S-100 matrix: A synergistic strategy for enhanced oral delivery. Future Sci OA 2021,7(4),FSO677-FSO687","journal-title":"Future Sci OA"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1016\/j.fct.2011.08.006","volume":"49","author":"Kakkar V.","year":"2011","unstructured":"Kakkar V.; Kaur I.P.; Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain. Food Chem Toxicol 2011,49(11),2906-2913","journal-title":"Food Chem Toxicol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1755-5949.2010.00147.x","volume":"16","author":"Hamaguchi T.","year":"2010","unstructured":"Hamaguchi T.; Ono K.; Yamada M.; REVIEW: Curcumin and Alzheimer\u2019s disease. CNS Neurosci Ther 2010,16(5),285-297","journal-title":"CNS Neurosci Ther"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.ijbiomac.2018.08.146","volume":"120","author":"Tian M.P.","year":"2018","unstructured":"Tian M.P.; Song R.X.; Wang T.; Sun M.J.; Liu Y.; Chen X.G.; Inducing sustained release and improving oral bioavailability of curcumin via chitosan derivatives-coated liposomes. Int J Biol Macromol 2018,120(Pt A),702-710","journal-title":"Int J Biol Macromol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/nu11010068","volume":"11","author":"Hsu C.Y.","year":"2019","unstructured":"Hsu C.Y.; Wang P.W.; Alalaiwe A.; Lin Z.C.; Fang J.Y.; Use of lipid nanocarriers to improve oral delivery of vitamins. Nutrients 2019,11(1),68-97","journal-title":"Nutrients"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.2174\/1381612826666200212120947","volume":"26","author":"Alexander A.","year":"2020","unstructured":"Alexander A.; Agrawal M.; Saraf S.; Saraf S.; Ajazuddin ; Chougule M.B.; Ajazuddin. ; Formulation strategies of nano lipid carrier for effective brain targeting of anti-AD drugs. Curr Pharm Des 2020,26(27),3269-3280","journal-title":"Curr Pharm Des"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1080\/10717544.2017.1391890","volume":"24","author":"Tian C.","year":"2017","unstructured":"Tian C.; Asghar S.; Wu Y.; Kambere Amerigos D.; Chen Z.; Zhang M.; Yin L.; Huang L.; Ping Q.; Xiao Y.; N-acetyl-L-cysteine functionalized nanostructured lipid preparation, in vitro and in vivo evaluations. Drug Deliv 2017,24,1605-1616","journal-title":"Drug Deliv"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/pharmaceutics13122049","volume":"13","author":"Lee D.","year":"2021","unstructured":"Lee D.; Minko T.; Nanotherapeutics for nose-to-brain drug delivery: An approach to bypass the blood brain barrier. Pharmaceutics 2021,13(12),2049-2095","journal-title":"Pharmaceutics"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"2003937","DOI":"10.1002\/advs.202003937","volume":"8","author":"Zhang W.","year":"2021","unstructured":"Zhang W.; Mehta A.; Tong Z.; Esser L.; Voelcker N.H.; Development of polymeric nanoparticles for blood-brain barrier transfer\u2014strategies and challenges. Adv Sci (Weinh) 2021,8(10),2003937-2003968","journal-title":"Adv Sci (Weinh)"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejpb.2022.02.004","volume":"172","author":"Brookes A.","year":"2022","unstructured":"Brookes A.; Ji L.; Bradshaw T.D.; Stocks M.; Gray D.; Butler J.; Gershkovich P.; Is oral lipid-based delivery for drug targeting to the brain feasible? Eur J Pharm Biopharm 2022,172,112-122","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018026762","volume":"36","author":"Dhas N.L.","year":"2019","unstructured":"Dhas N.L.; Kudarha R.R.; Mehta T.A.; Intranasal delivery of nanotherapeutics\/ nanobiotherapeutics for the treatment of Alzheimer\u2019s disease: A proficient approach. Crit Rev Ther Drug Carrier Syst 2019,36(5),373-447","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.2174\/1381612826666200313125613","volume":"26","author":"Gorain B.","year":"2020","unstructured":"Gorain B.; Rajeswary D.C.; Pandey M.; Kesharwani P.; Kumbhar S.A.; Choudhury H.; Nose to brain delivery of nanocarriers towards attenuation of demented condition. Curr Pharm Des 2020,26(19),2233-2246","journal-title":"Curr Pharm Des"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"120994","DOI":"10.1016\/j.ijpharm.2021.120994","volume":"607","author":"Laffleur F.","year":"2021","unstructured":"Laffleur F.; Bauer B.; Progress in nasal drug delivery systems. Int J Pharm 2021,607,120994-121010","journal-title":"Int J Pharm"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","volume":"281","author":"Agrawal M.","year":"2018","unstructured":"Agrawal M.; Saraf S.; Saraf S.; Antimisiaris S.G.; Chougule M.B.; Shoyele S.A.; Alexander A.; Nose- to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release 2018,281,139-177","journal-title":"J Control Release"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s13346-021-00940-7","volume":"11","author":"Fonseca L.C.","year":"2021","unstructured":"Fonseca L.C.; Lopes J.A.; Vieira J.; Viegas C.; Oliveira C.S.; Hartmann R.P.; Fonte P.; Intranasal drug delivery for treatment of Alzheimer\u2019s disease. Drug Deliv Transl Res 2021,11(2),411-425","journal-title":"Drug Deliv Transl Res"},{"key":"ref=154","first-page":"110","volume":"3","author":"Ghori M.U.","year":"2015","unstructured":"Ghori M.U.; Mahdi M.H.; Smith A.M.; Conway B.R.; Nasal drug delivery systems: An overview. Am J Pharmacol Sci 2015,3,110-119","journal-title":"Am J Pharmacol Sci"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3109\/1061186X.2013.876644","volume":"22","author":"Sood S.","year":"2014","unstructured":"Sood S.; Jain K.; Gowthamarajan K.; Intranasal therapeutic strategies for management of Alzheimer\u2019s disease. J Drug Target 2014,22(4),279-294","journal-title":"J Drug Target"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.2174\/1381612827666210927163258","volume":"27","author":"Jain D.","year":"2021","unstructured":"Jain D.; Rashid M.A.; Ahmad F.J.; Recent advances in targeted drug delivery approaches using lipidic and polymeric nanocarriers for the management of Alzheimer\u2019s disease. Curr Pharm Des 2021,27(43),4388-4403","journal-title":"Curr Pharm Des"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ijpharm.2019.02.012","volume":"560","author":"Yu S.","year":"2019","unstructured":"Yu S.; Xu X.; Feng J.; Liu M.; Hu K.; Chitosan and chitosan coating nanoparticles for the treatment of brain disease. Int J Pharm 2019,560,282-293","journal-title":"Int J Pharm"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2147\/IJN.S151474","volume":"13","author":"Meng Q.","year":"2018","unstructured":"Meng Q.; Wang A.; Hua H.; Jiang Y.; Wang Y.; Mu H.; Wu Z.; Sun K.; Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer\u2019s disease. Int J Nanomed 2018,13,705-718","journal-title":"Int J Nanomed"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0168-3659(99)00228-X","volume":"65","author":"Lehr C.M.","year":"2000","unstructured":"Lehr C.M.; Lectin-mediated drug delivery. J Control Release 2000,65(1-2),19-29","journal-title":"J Control Release"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"111829","DOI":"10.1016\/j.biopha.2021.111829","volume":"141","author":"Gao Y.","year":"2021","unstructured":"Gao Y.; Almalki W.H.; Afzal O.; Panda S.K.; Kazmi I.; Alrobaian M.; Katouah H.A.; Altamimi A.S.A.; Al-Abbasi F.A.; Alshehri S.; Soni K.; Ibrahim I.A.A.; Rahman M.; Beg S.; Systematic development of lectin conjugated microspheres for nose-to-brain delivery of rivastigmine for the treatment of Alzheimer\u2019s disease. Biomed Pharmacother 2021,141,111829-111839","journal-title":"Biomed Pharmacother"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"1800340","DOI":"10.1002\/mabi.201800340","volume":"19","author":"Chen Y.","year":"2019","unstructured":"Chen Y.; Fan H.; Xu C.; Hu W.; Yu B.; Efficient cholera toxin B subunit-based nanoparticles with MRI capability for drug delivery to the brain following intranasal administration. Macromol Biosci 2019,19(2),1800340-1800340","journal-title":"Macromol Biosci"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1208\/s12249-022-02209-9","volume":"23","author":"Rajput A.","year":"2022","unstructured":"Rajput A.; Butani S.; Donepezil HCl liposomes: Development, characterization, cytotoxicity, and pharmacokinetic study. AAPS PharmSciTech 2022,23(2),74","journal-title":"AAPS PharmSciTech"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"9563","DOI":"10.1038\/s41598-019-46032-y","volume":"9","author":"Al Harthi S.","year":"2019","unstructured":"Al Harthi S.; Alavi S.E.; Radwan M.A.; El Khatib M.M.; AlSarra I.A.; Nasal delivery of donepezil HCl-loaded hydrogels for the treatment of Alzheimer\u2019s disease. Sci Rep 2019,9(1),9563-9582","journal-title":"Sci Rep"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2478\/acph-2020-0032","volume":"70","author":"Gu F.","year":"2020","unstructured":"Gu F.; Fan H.; Cong Z.; Li S.; Wang Y.; Wu C.; Preparation, characterization, and in vivo pharmacokinetics of thermosensitive in situ nasal gel of donepezil hydrochloride. Acta Pharm 2020,70(3),411-422","journal-title":"Acta Pharm"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"119115","DOI":"10.1016\/j.ijpharm.2020.119115","volume":"578","author":"Chen W.","year":"2020","unstructured":"Chen W.; Li R.; Zhu S.; Ma J.; Pang L.; Ma B.; Du L.; Jin Y.; Nasal timosaponin BII dually sensitive in situ hydrogels for the prevention of Alzheimer\u2019s disease induced by lipopolysaccharides. Int J Pharm 2020,578,119115-119123","journal-title":"Int J Pharm"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2174\/1871527317666180104122347","volume":"17","author":"Espinoza L.C.","year":"2018","unstructured":"Espinoza L.C.; Vacacela M.; Clares B.; Garcia M.L.; Fabrega M.J.; Calpena A.C.; Development of a nasal donepezil-loaded microemulsion for the treatment of Alzheimer\u2019s disease: in vitro and ex vivo characterization. CNS Neurol Disord Drug Targets 2018,17(1),43-53","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/pharmaceutics11020064","volume":"11","author":"Espinoza L.C.","year":"2019","unstructured":"Espinoza L.C.; Silva-Abreu M.; Clares B.; Rodr\u00edguez-Lagunas M.J.; Halbaut L.; Ca\u00f1as M.A.; Calpena A.C.; Formulation strategies to improve nose-to-brain delivery of donepezil. Pharmaceutics 2019,11(2),64-79","journal-title":"Pharmaceutics"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1208\/s12249-019-1585-7","volume":"21","author":"Khunt D.","year":"2020","unstructured":"Khunt D.; Shrivas M.; Polaka S.; Gondaliya P.; Misra M.; Role of omega-3 fatty acids and butter oil in targeting delivery of donepezil hydrochloride microemulsion to brain via the intranasal route: A comparative study. AAPS PharmSciTech 2020,21(2),45-55","journal-title":"AAPS PharmSciTech"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"918","DOI":"10.3109\/10717544.2013.878857","volume":"22","author":"Shah B.M.","year":"2015","unstructured":"Shah B.M.; Misra M.; Shishoo C.J.; Padh H.; Nose to brain microemulsion-based drug delivery system of rivastigmine: Formulation and ex-vivo characterization. Drug Deliv 2015,22(7),918-930","journal-title":"Drug Deliv"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11095-017-2279-z","volume":"35","author":"Shah B.","year":"2018","unstructured":"Shah B.; Khunt D.; Misra M.; Padh H.; Formulation and in-vivo pharmacokinetic consideration of intranasal microemulsion and mucoadhesive microemulsion of rivastigmine for brain targeting. Pharm Res 2018,35(1),8-17","journal-title":"Pharm Res"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"129721","DOI":"10.1016\/j.foodchem.2021.129721","volume":"357","author":"Kotta S.","year":"2021","unstructured":"Kotta S.; Mubarak Aldawsari H.; Badr-Eldin S.M.; Alhakamy N.A.; Md S.; Coconut oil-based resveratrol nanoemulsion: Optimization using response surface methodology, stability assessment and pharmacokinetic evaluation. Food Chem 2021,357,129721-129733","journal-title":"Food Chem"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1007\/s13346-020-00754-z","volume":"10","author":"Kaur A.","year":"2020","unstructured":"Kaur A.; Nigam K.; Bhatnagar I.; Sukhpal H.; Awasthy S.; Shankar S.; Tyagi A.; Dang S.; Treatment of Alzheimer\u2019s diseases using donepezil nanoemulsion: An intranasal approach. Drug Deliv Transl Res 2020,10(6),1862-1875","journal-title":"Drug Deliv Transl Res"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3390\/polym14030443","volume":"14","author":"Phongpradist R.","year":"2022","unstructured":"Phongpradist R.; Thongchai W.; Thongkorn K.; Lekawanvijit S.; Chittasupho C.; Surface modification of curcumin microemulsions by coupling of KLVFF peptide: A prototype for targeted bifunctional microemulsions. Polymers 2022,14(3),443-453","journal-title":"Polymers"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1042\/BCJ20200290","volume":"477","author":"Horsley J.R.","year":"2020","unstructured":"Horsley J.R.; Jovcevski B.; Wegener K.L.; Yu J.; Pukala T.L.; Abell A.D.; Rationally designed peptide-based inhibitor of A\u03b2 fibril formation and toxicity: A potential therapeutic strategy for Alzheimer\u2019s disease. Biochem J 2020,477(11),2039-2054","journal-title":"Biochem J"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1021\/acsomega.8b02797","volume":"4","author":"Huang Q.","year":"2019","unstructured":"Huang Q.; Zhao Q.; Peng J.; Yu Y.; Wang C.; Zou Y.; Su Y.; Zhu L.; Wang C.; Yang Y.; Peptide-polyphenol (KLVFF\/EGCG) binary modulators for inhibiting aggregation and neurotoxicity of amyloid-\u03b2 peptide. ACS Omega 2019,4(2),4233-4242","journal-title":"ACS Omega"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.biocel.2008.06.010","volume":"41","author":"Aggarwal B.B.","year":"2009","unstructured":"Aggarwal B.B.; Harikumar K.B.; Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009,41(1),40-59","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"338","DOI":"10.2174\/1570159X11311040002","volume":"11","author":"Lee W.H.","year":"2013","unstructured":"Lee W.H.; Loo C.Y.; Bebawy M.; Luk F.; Mason R.; Rohanizadeh R.; Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. Curr Neuropharmacol 2013,11(4),338-378","journal-title":"Curr Neuropharmacol"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"8370","DOI":"10.1523\/JNEUROSCI.21-21-08370.2001","volume":"21","author":"Lim G.P.","year":"2001","unstructured":"Lim G.P.; Chu T.; Yang F.; Beech W.; Frautschy S.A.; Cole G.M.; The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001,21(21),8370-8377","journal-title":"J Neurosci"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"147517","DOI":"10.1016\/j.brainres.2021.147517","volume":"1766","author":"Ahmadi N.","year":"2021","unstructured":"Ahmadi N.; Hosseini M.J.; Rostamizadeh K.; Anoush M.; Investigation of therapeutic effect of curcumin \u03b1 and \u03b2 glucoside anomers against Alzheimer\u2019s disease by the nose to brain drug delivery. Brain Res 2021,1766,147517","journal-title":"Brain Res"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2478\/v10007-008-0014-3","volume":"58","author":"Arumugam K.","year":"2008","unstructured":"Arumugam K.; Subramanian G.; Mallayasamy S.; Averineni R.; Reddy M.; Udupa N.; A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm 2008,58(3),287-297","journal-title":"Acta Pharm"},{"key":"ref=181","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/DDDT.S113171","volume":"10","author":"Al Asmari A.K.","year":"2016","unstructured":"Al Asmari A.K.; Ullah Z.; Tariq M.; Fatani A.; Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Des Devel Ther 2016,10,205-215","journal-title":"Drug Des Devel Ther"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1080\/10717544.2017.1309476","volume":"24","author":"Nageeb El-Helaly S.","year":"2017","unstructured":"Nageeb El-Helaly S.; Abd Elbary A.; Kassem M.A.; El-Nabarawi M.A.; Electrosteric stealth Rivastigmine loaded liposomes for brain targeting: Preparation, characterization, ex vivo, bio-distribution and in vivo pharmacokinetic studies. Drug Deliv 2017,24(1),692-700","journal-title":"Drug Deliv"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.etap.2012.04.012","volume":"34","author":"Li W.","year":"2012","unstructured":"Li W.; Zhou Y.; Zhao N.; Hao B.; Wang X.; Kong P.; Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environ Toxicol Pharmacol 2012,34(2),272-279","journal-title":"Environ Toxicol Pharmacol"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2021.02.015","volume":"163","author":"Kulkarni P.","year":"2021","unstructured":"Kulkarni P.; Rawtani D.; Barot T.; Design, development and in-vitro\/in-vivo evaluation of intranasally delivered Rivastigmine and N-Acetyl cysteine loaded bifunctional niosomes for applications in combinative treatment of Alzheimer\u2019s disease. Eur J Pharm Biopharm 2021,163,1-15","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ijpharm.2013.05.009","volume":"452","author":"Yang Z.Z.","year":"2013","unstructured":"Yang Z.Z.; Zhang Y.Q.; Wang Z.Z.; Wu K.; Lou J.N.; Qi X.R.; Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int J Pharm 2013,452(1-2),344-354","journal-title":"Int J Pharm"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1007\/s11095-015-1744-9","volume":"32","author":"Zheng X.","year":"2015","unstructured":"Zheng X.; Shao X.; Zhang C.; Tan Y.; Liu Q.; Wan X.; Zhang Q.; Xu S.; Jiang X.; Intranasal H102 peptide-loaded liposomes for brain delivery to treat Alzheimer\u2019s disease. Pharm Res 2015,32(12),3837-3849","journal-title":"Pharm Res"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3109\/08982104.2014.899369","volume":"24","author":"Corace G.","year":"2014","unstructured":"Corace G.; Angeloni C.; Malaguti M.; Hrelia S.; Stein P.C.; Brandl M.; Gotti R.; Luppi B.; Multifunctional liposomes for nasal delivery of the anti-Alzheimer drug tacrine hydrochloride. J Liposome Res 2014,24(4),323-335","journal-title":"J Liposome Res"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1016\/0006-2952(88)90356-5","volume":"37","author":"Dogterom P.","year":"1988","unstructured":"Dogterom P.; Nagelkerke J.F.; Mulder G.J.; Hepatotoxicity of tetrahydroaminoacridine in isolated rat hepatocytes: Effect of glutathione and vitamin E. Biochem Pharmacol 1988,37(12),2311-2313","journal-title":"Biochem Pharmacol"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s11745-001-0846-x","volume":"36","author":"Nacka F.","year":"2001","unstructured":"Nacka F.; Cansell M.; M\u00e9l\u00e9ard P.; Combe N.; Incorporation of \u03b1-tocopherol in marine lipid-based liposomes: in vitro and in vivo studies. Lipids 2001,36(12),1313-1320","journal-title":"Lipids"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"824.e1","DOI":"10.1016\/j.neurobiolaging.2011.03.019","volume":"33","author":"Stough C.","year":"2012","unstructured":"Stough C.; Downey L.; Silber B.; Lloyd J.; Kure C.; Wesnes K.; Camfield D.; The effects of 90-day supplementation with the Omega-3 essential fatty acid docosahexaenoic acid (DHA) on cognitive function and visual acuity in a healthy aging population. Neurobiol Aging 2012,33(4),824.e1-824.e3","journal-title":"Neurobiol Aging"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"24600","DOI":"10.3390\/ijms161024600","volume":"16","author":"Phillips M.","year":"2015","unstructured":"Phillips M.; Childs C.; Calder P.; Rogers P.; No effect of Omega-3 fatty acid supplementation on cognition and mood in individuals with cognitive impairment and probable Alzheimer\u2019s Disease: A randomised controlled trial. Int J Mol Sci 2015,16(10),24600-24613","journal-title":"Int J Mol Sci"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.2174\/0929867327666200831140745","volume":"28","author":"Rampa A.","year":"2021","unstructured":"Rampa A.; Gobbi S.; Belluti F.; Bisi A.; Tackling Alzheimer\u2019s disease with existing drugs: A promising strategy for bypassing obstacles. Curr Med Chem 2021,28(12),2305-2327","journal-title":"Curr Med Chem"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.lfs.2018.06.032","volume":"207","author":"Qian S.","year":"2018","unstructured":"Qian S.; He L.; Wang Q.; Wong Y.C.; Mak M.; Ho C.Y.; Han Y.; Zuo Z.; Intranasal delivery of a novel acetylcholinesterase inhibitor HLS-3 for treatment of Alzheimer\u2019s disease. Life Sci 2018,207,428-435","journal-title":"Life Sci"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.3390\/molecules27031060","volume":"27","author":"Makhaeva G.F.","year":"2022","unstructured":"Makhaeva G.F.; Kovaleva N.V.; Boltneva N.P.; Rudakova E.V.; Lushchekina S.V.; Astakhova T.Y.; Serkov I.V.; Proshin A.N.; Radchenko E.V.; Palyulin V.A.; Korabecny J.; Soukup O.; Bachurin S.O.; Richardson R.J.; Bis-Amiridines as acetylcholinesterase and butyrylcholinesterase inhibitors: n-functionalization determines the multitarget anti-Alzheimer\u2019s activity profile. Molecules 2022,27(3),1060-1084","journal-title":"Molecules"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.mencom.2021.09.005","volume":"31","author":"Makhaeva G.F.","year":"2021","unstructured":"Makhaeva G.F.; Serkov I.V.; Kovaleva N.V.; Rudakova E.V.; Boltneva N.P.; Kochetkova E.A.; Proshin A.N.; Bachurin S.O.; Novel conjugates of 4-amino-2,3-polymethylenequinolines and vanillin as potential multitarget agents for AD treatment. Mendeleev Commun 2021,31(5),606-608","journal-title":"Mendeleev Commun"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"13757","DOI":"10.1039\/D0NR04037A","volume":"12","author":"Burilova E.A.","year":"2020","unstructured":"Burilova E.A.; Pashirova T.N.; Zueva I.V.; Gibadullina E.M.; Lushchekina S.V.; Sapunova A.S.; Kayumova R.M.; Rogov A.M.; Evtjugin V.G.; Sudakov I.A.; Vyshtakalyuk A.B.; Voloshina A.D.; Bukharov S.V.; Burilov A.R.; Petrov K.A.; Zakharova L.Y.; Sinyashin O.G.; Bi- functional sterically hindered phenol lipid-based delivery systems as potential multi-target agents against Alzheimer\u2019s disease via an intranasal route. Nanoscale 2020,12(25),13757-13770","journal-title":"Nanoscale"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"100579","DOI":"10.1016\/j.colcom.2021.100579","volume":"46","author":"Zhao J.","year":"2022","unstructured":"Zhao J.; Xu N.; Yang X.; Ling G.; Zhang P.; The roles of gold nanoparticles in the detection of amyloid-\u03b2 peptide for Alzheimer\u2019s disease. Colloid Interface Sci Commun 2022,46,100579-100587","journal-title":"Colloid Interface Sci Commun"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"102599","DOI":"10.1016\/j.jddst.2021.102599","volume":"64","author":"Daund V.","year":"2021","unstructured":"Daund V.; Chalke S.; Sherje A.P.; Kale P.P.; ROS responsive mesoporous silica nanoparticles for smart drug delivery: A review. J Drug Deliv Sci Technol 2021,64,102599-102612","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.7150\/thno.31653","volume":"9","author":"Yu G.","year":"2019","unstructured":"Yu G.; Chen X.; Host-guest chemistry in supramolecular theranostics. Theranostics 2019,9(11),3041-3074","journal-title":"Theranostics"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JAD-2006-102-303","volume":"10","author":"Adlard P.A.","year":"2006","unstructured":"Adlard P.A.; Bush A.I.; Metals and Alzheimer\u2019s disease. J Alzheimers Dis 2006,10(2-3),145-163","journal-title":"J Alzheimers Dis"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.1039\/D2DT00162D","volume":"51","author":"Nath A.K.","year":"2022","unstructured":"Nath A.K.; Dey S.G.; Simultaneous binding of heme and Cu with amyloid \u03b2 peptides: Active site and reactivities. Dalton Trans 2022,51(13),4986-4999","journal-title":"Dalton Trans"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1039\/C4MT00122B","volume":"6","author":"Yu M.","year":"2014","unstructured":"Yu M.; Ryan T.M.; Ellis S.; Bush A.I.; Triccas J.A.; Rutledge P.J.; Todd M.H.; Neuroprotective peptide-macrocycle conjugates reveal complex structure-activity relationships in their interactions with amyloid \u03b2. Metallomics 2014,6(10),1931-1940","journal-title":"Metallomics"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1039\/D1QI00237F","volume":"8","author":"Xu W.","year":"2021","unstructured":"Xu W.; Gao C.; Sun X.; Tai W.C.S.; Lung H.L.; Law G.L.; Design, synthesis and comparison of water-soluble phthalocyanine\/porphyrin analogues and their inhibition effects on A\u03b2 fibrillization. Inorg Chem Front 2021,8(14),3501-3513","journal-title":"Inorg Chem Front"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"11003","DOI":"10.1039\/D0SC04984K","volume":"11","author":"Liu Z.","year":"2020","unstructured":"Liu Z.; Ma M.; Yu D.; Ren J.; Qu X.; Target-driven supramolecular self-assembly for selective amyloid-\u03b2 photooxygenation against Alzheimer\u2019s disease. Chem Sci (Camb) 2020,11(40),11003-11008","journal-title":"Chem Sci (Camb)"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1002\/chem.201406152","volume":"21","author":"Martins A.F.","year":"2015","unstructured":"Martins A.F.; Dias D.M.; Morfin J.F.; Lacerda S.; Laurents D.V.; T\u00f3th \u00c9.; Geraldes C.F.G.C.; Interaction of PiB-derivative metal complexes with beta-amyloid peptides: selective recognition of the aggregated forms. Chemistry 2015,21(14),5413-5422","journal-title":"Chemistry"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/10610278.2020.1725515","volume":"32","author":"Razuvayeva Y.","year":"2020","unstructured":"Razuvayeva Y.; Kashapov R.; Zakharova L.; Calixarene-based pure and mixed assemblies for biomedical applications. Supramol Chem 2020,32(3),178-206","journal-title":"Supramol Chem"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/biom9030090","volume":"9","author":"Espa\u00f1ol E.","year":"2019","unstructured":"Espa\u00f1ol E.; Villamil M.; Calixarenes: Generalities and their role in improving the solubility, biocompatibility, stability, bioavailability, detection, and transport of biomolecules. Biomolecules 2019,9(3),90-104","journal-title":"Biomolecules"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/asia.201601461","volume":"12","author":"Wang Z.","year":"2017","unstructured":"Wang Z.; Tao S.; Dong X.; Sun Y.; Para-sulfonatocalix[n]arenes inhibit amyloid \u03b2-peptide fibrillation and reduce amyloid cytotoxicity. Chem Asian J 2017,12(3),341-346","journal-title":"Chem Asian J"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10847-018-00879-2","volume":"93","author":"Schubert E.A.","year":"2019","unstructured":"Schubert E.A.; Kayser V.; Wheate N.J.; Analysis of the interaction of para-sulfonatocalix[8]arene with free amino acids and a six residue segment of \u03b2-amyloid peptide as a potential treatment for Alzheimer\u2019s disease. J Incl Phenom Macrocycl Chem 2019,93(3-4),265-273","journal-title":"J Incl Phenom Macrocycl Chem"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.3390\/ijms20133139","volume":"20","author":"Fanizza E.","year":"2019","unstructured":"Fanizza E.; Depalo N.; Fedorenko S.; Iacobazzi R.M.; Mukhametshina A.; Zairov R.; Salatino A.; Vischio F.; Panniello A.; Laquintana V.; Curri M.L.; Mustafina A.; Denora N.; Striccoli M.; Green fluorescent terbium (III) complex doped silica nanoparticles. Int J Mol Sci 2019,20(13),3139-3154","journal-title":"Int J Mol Sci"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41557-018-0164-y","volume":"11","author":"Xu Z.","year":"2019","unstructured":"Xu Z.; Jia S.; Wang W.; Yuan Z.; Jan Ravoo B.; Guo D.S.; Heteromultivalent peptide recognition by co-assembly of cyclodextrin and calixarene amphiphiles enables inhibition of amyloid fibrillation. Nat Chem 2019,11(1),86-93","journal-title":"Nat Chem"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1021\/acschemneuro.1c00117","volume":"12","author":"Consoli G.M.L.","year":"2021","unstructured":"Consoli G.M.L.; Tosto R.; Baglieri A.; Petralia S.; Campagna T.; Di Natale G.; Zimbone S.; Giuffrida M.L.; Pappalardo G.; Novel peptide-calix[4]arene conjugate inhibits a\u03b2 aggregation and rescues neurons from A\u03b2\u2019s oligomers cytotoxicity in vitro. ACS Chem Neurosci 2021,12(8),1449-1462","journal-title":"ACS Chem Neurosci"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10847-021-01096-0","volume":"101","author":"Wheate N.J.","year":"2021","unstructured":"Wheate N.J.; Comparative host-guest complex formation of the Alzheimer\u2019s drug memantine with para-sulfonatocalix[n]arenes (n = 4 or 8). J Incl Phenom Macrocycl Chem 2021,101(1-2),131-137","journal-title":"J Incl Phenom Macrocycl Chem"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"112724","DOI":"10.1016\/j.molliq.2020.112724","volume":"304","author":"Ostos F.J.","year":"2020","unstructured":"Ostos F.J.; Lebr\u00f3n J.A.; L\u00f3pez-Cornejo P.; L\u00f3pez-L\u00f3pez M.; Garc\u00eda-Calder\u00f3n M.; Garc\u00eda-Calder\u00f3n C.B.; Rosado I.V.; Kalchenko V.I.; Rodik R.V.; Moy\u00e1 M.L.; Self-aggregation in aqueous solution of amphiphilic cationic calix[4]arenes. Potential use as vectors and nanocarriers. J Mol Liq 2020,304,112724-112737","journal-title":"J Mol Liq"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"9657","DOI":"10.1021\/acs.chemrev.8b00605","volume":"119","author":"Kumar R.","year":"2019","unstructured":"Kumar R.; Sharma A.; Singh H.; Suating P.; Kim H.S.; Sunwoo K.; Shim I.; Gibb B.C.; Kim J.S.; Revisiting fluorescent calixarenes: From molecular sensors to smart materials. Chem Rev 2019,119(16),9657-9721","journal-title":"Chem Rev"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1136\/jnnp.2006.099424","volume":"78","author":"Feldman H.H.","year":"2007","unstructured":"Feldman H.H.; Lane R.; Rivastigmine: A placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry 2007,78(10),1056-1063","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"459","DOI":"10.9758\/cpn.2021.19.3.459","volume":"19","author":"Hsieh S.W.","year":"2021","unstructured":"Hsieh S.W.; Chen J.C.; Chen N.C.; Jhang K.M.; Wang W.; Yang Y.H.; Real-world evaluation of tolerability, safety and efficacy of rivastigmine oral solution in patients with mild to moderate Alzheimer\u2019s disease dementia. Clin Psychopharmacol Neurosci 2021,19(3),459-469","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"102695","DOI":"10.1016\/j.jddst.2021.102695","volume":"66","author":"Lohan S.","year":"2021","unstructured":"Lohan S.; Sharma T.; Saini S.; Singh A.; Kumar A.; Raza K.; Kaur J.; Singh B.; Galactosylated nanoconstructs of berberine with enhanced biopharmaceutical and cognitive potential: A preclinical evidence in Alzheimer\u2018s disease. J Drug Deliv Sci Technol 2021,66,102695-102704","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"120482","DOI":"10.1016\/j.ijpharm.2021.120482","volume":"600","author":"Lohan S.","year":"2021","unstructured":"Lohan S.; Sharma T.; Saini S.; Swami R.; Dhull D.; Beg S.; Raza K.; Kumar A.; Singh B.; QbD-steered development of mixed nanomicelles of galantamine: Demonstration of enhanced brain uptake, prolonged systemic retention and improved biopharmaceutical attributes. Int J Pharm 2021,600,120482-120493","journal-title":"Int J Pharm"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.3109\/10717544.2016.1153748","volume":"23","author":"Hanafy A.S.","year":"2016","unstructured":"Hanafy A.S.; Farid R.M.; Helmy M.W.; ElGamal S.S.; Pharmacological, toxicological and neuronal localization assessment of galantamine\/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer\u2019s disease management. Drug Deliv 2016,23(8),3111-3122","journal-title":"Drug Deliv"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejps.2012.04.013","volume":"47","author":"Fazil M.","year":"2012","unstructured":"Fazil M.; Md S.; Haque S.; Kumar M.; Baboota S.; Sahni J.; Ali J.; Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 2012,47(1),6-15","journal-title":"Eur J Pharm Sci"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41541-020-0172-y","volume":"5","author":"Takeuchi H.","year":"2020","unstructured":"Takeuchi H.; Imamura K.; Ji B.; Tsukita K.; Enami T.; Takao K.; Miyakawa T.; Hasegawa M.; Sahara N.; Iwata N.; Inoue M.; Hara H.; Tabira T.; Ono M.; Trojanowski J.Q.; Lee V.M.Y.; Takahashi R.; Suhara T.; Higuchi M.; Inoue H.; Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice. NPJ Vaccines 2020,5(1),28-38","journal-title":"NPJ Vaccines"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.2147\/IJN.S171490","volume":"13","author":"Silva-Abreu M.","year":"2018","unstructured":"Silva-Abreu M.; Calpena A.C.; Andr\u00e9s-Benito P.; Aso E.; Romero I.A.; Roig-Carles D.; Gromnicova R.; Espina M.; Ferrer I.; Garc\u00eda M.L.; Male D.; PPAR\u03b3 agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer\u2019s disease: In vitro and in vivo studies. Int J Nanomed 2018,13,5577-5590","journal-title":"Int J Nanomed"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"111838","DOI":"10.1016\/j.colsurfb.2021.111838","volume":"205","author":"Saini S.","year":"2021","unstructured":"Saini S.; Sharma T.; Jain A.; Kaur H.; Katare O.P.; Singh B.; Systematically designed chitosan-coated solid lipid nanoparticles of ferulic acid for effective management of Alzheimer\u2019s disease: A preclinical evidence. Colloids Surf B Biointerfaces 2021,205,111838-101849","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=225","first-page":"283","volume":"15","author":"Sadeghi M.","year":"2016","unstructured":"Sadeghi M.; Ganji F.; Taghizadeh S.M.; Daraei B.; Preparation and characterization of rivastigmine transdermal patch based on chitosan microparticles. Iran J Pharm Res 2016,15,283-294","journal-title":"Iran J Pharm Res"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejpb.2016.03.026","volume":"103","author":"Kearney M.C.","year":"2016","unstructured":"Kearney M.C.; Caffarel-Salvador E.; Fallows S.J.; McCarthy H.O.; Donnelly R.F.; Microneedle-mediated delivery of donepezil: Potential for improved treatment options in Alzheimer\u2019s disease. Eur J Pharm Biopharm 2016,103,43-50","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.2147\/DDDT.S244957","volume":"14","author":"Yoon S.K.","year":"2020","unstructured":"Yoon S.K.; Bae K.S.; Hong D.H.; Kim S.S.; Choi Y.K.; Lim H.S.; Pharmacokinetic evaluation by modeling and simulation analysis of a donepezil patch formulation in healthy male volunteers. Drug Des Devel Ther 2020,14,1729-1737","journal-title":"Drug Des Devel Ther"},{"key":"ref=228","first-page":"397","author":"Kumar M.","year":"2018","unstructured":"Kumar M.; Sharma P.; Maheshwari R.; Tekade M.; Shrivastava S.K.; Tekade R.K.; Beyond the blood-brain barrier: Facing new challenges and prospects of nanotechnology-mediated targeted delivery to the brain. Nanotechnology-based targeted drug delivery systems for brain tumors 2018,397-437","journal-title":"Nanotechnology-based targeted drug delivery systems for brain tumors"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.2174\/1389450115666140804124808","volume":"16","author":"Wolfram J.","year":"2015","unstructured":"Wolfram J.; Zhu M.; Yang Y.; Shen J.; Gentile E.; Paolino D.; Fresta M.; Nie G.; Chen C.; Shen H.; Ferrari M.; Zhao Y.; Safety of nanoparticles in medicine. Curr Drug Targets 2015,16(14),1671-1681","journal-title":"Curr Drug Targets"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.3390\/pharmaceutics13122014","volume":"13","author":"Bajracharya R.","year":"2021","unstructured":"Bajracharya R.; Caruso A.C.; Vella L.J.; Nisbet R.M.; Current and emerging strategies for enhancing antibody delivery to the brain. Pharmaceutics 2021,13(12),2014-2029","journal-title":"Pharmaceutics"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"e12295","DOI":"10.1002\/trc2.12295","volume":"8","author":"Cummings J.","year":"2022","unstructured":"Cummings J.; Lee G.; Nahed P.; Kambar M.E.Z.N.; Zhong K.; Fonseca J.; Taghva K.; Alzheimer\u2019s disease drug development pipeline: 2022. Alzheimers Dement (N Y) 2022,8(1),e12295-e12318","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/bpa.12895","volume":"30","author":"Kirabali T.","year":"2020","unstructured":"Kirabali T.; Rust R.; Rigotti S.; Siccoli A.; Nitsch R.M.; Kulic L.; Distinct changes in all major components of the neurovascular unit across different neuropathological stages of Alzheimer\u2019s disease. Brain Pathol 2020,30(6),1056-1070","journal-title":"Brain Pathol"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1021\/acsanm.9b02243","volume":"3","author":"Choi S.W.","year":"2020","unstructured":"Choi S.W.; Kim J.; Recent progress in autocatalytic ceria nanoparticles-based translational research on brain diseases. ACS Appl Nano Mater 2020,3(2),1043-1062","journal-title":"ACS Appl Nano Mater"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"2003054","DOI":"10.1002\/adfm.202003054","volume":"30","author":"Mukherjee S.","year":"2020","unstructured":"Mukherjee S.; Madamsetty V.S.; Bhattacharya D.; Roy Chowdhury S.; Paul M.K.; Mukherjee A.; Recent advancements of nanomedicine in neurodegenerative disorders theranostics. Adv Funct Mater 2020,30(35),2003054-2003080","journal-title":"Adv Funct Mater"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666221115103513","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/210899\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666221115103513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T04:11:27Z","timestamp":1728360687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/210899\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":234,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867330666221115103513","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}